FDA Approves MYCOPHENOLATE MOFETIL — Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA, Inc. announced the approval of a new Andrond application for generic Mycophenolate Mofetil, a low-cost oral immune suppressant that has broad market implications for reducing costs in transplant and autoimmune therapies amid recent drug price volatility.